Evidence map›Paper›PMID 40049420›Full record

ArticleThe Journal of allergy and clinical immunology2025

The drug allergy history tool (DAHT): Validation of a patient-reported survey instrument.

Kimberly G Blumenthal, Daniel A Gundersen, Liam R Smith, Brett Nava-Coulter, Andrew King, Elizabeth J Phillips, Alexei Gonzalez-Estrada, Iris M Otani, Allison Ramsey, Aleena Banerji and 4 more

Abstract readValidation Study
In one paragraph

Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kimberly G BlumenthalDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass. Electronic address: kblumenthal@mgh.harvard.edu.
Daniel A GundersenHarvard Medical School, Boston, Mass; Survey and Qualitative Methods Core, Dana Farber Cancer Institute, Boston, Mass.
Liam R SmithDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass.
Brett Nava-CoulterSurvey and Qualitative Methods Core, Dana Farber Cancer Institute, Boston, Mass.
Andrew KingDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Elizabeth J PhillipsCenter for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.
Alexei Gonzalez-EstradaDivision of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic, Scottsdale, Ariz.
Iris M OtaniDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco Medical Center, San Francisco, Calif.
Allison RamseyRochester Regional Health, Rochester, NY; Department of Allergy/Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY.
Aleena BanerjiDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
Timothy G ChowDivision of Allergy and Immunology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Tex.
Cosby A StoneCenter for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.
Whitney A SalinasDivision of Allergy and Immunology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Tex.
David A KhanDivision of Allergy and Immunology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Tex.

Funding

NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial)U01AI184071 · NIAID · MAYO CLINIC JACKSONVILLE · PI Kimberly G. Blumenthal, DAVID A KHAN · 2024 to 2026
$9.4M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
Vanderbilt University Medical Center (VUMC) CoFAR Clinical Research CenterU01AI181927 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Leonard B Bacharier, Rachel Glick Robison · 2024 to 2026
$3.0M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
Determining the Accuracy of Cephalosporin Allergy TestingR34AI134569 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI KHAN, DAVID A · 2019 to 2019
$293k
AHRQ HHS R01 HS029319AHRQ HHS R01 HS030234NHGRI NIH HHS R01 HG010863NIAID NIH HHS R01 AI152183NIAID NIH HHS R34 AI134569NIAID NIH HHS U01 AI154659NIAID NIH HHS U01 AI181927NIAID NIH HHS U01 AI184071
6 · The paper itself

Abstract

backgroundWhile the reaction history is critical for drug allergy evaluations and is typically self-reported, there is no validated survey instrument to collect drug allergy history from patients.

objectiveWe validated a survey instrument that collects patient-reported drug allergy history.

methodsThe drug allergy history tool (DAHT) was revised after 3 rounds of cognitive testing, assessed for reliability through test-retest comparisons, and assessed for quality and validity through a concordance analysis against electronic health record allergist documentation. Participants completing testing and surveys had 1 or more drug allergies and were recruited from allergy clinics at Massachusetts General Hospital. Primary evaluative measures were percentage agreement and kappa statistic values.

resultsThe DAHT was completed by 79 individuals (mean age, 49 [SD 17] years, 85% female, 85% White, 11% Hispanic ethnicity), 29 with single drug allergy labels and 50 with multiple drug allergy labels. The most common drug allergy labels were penicillins (77%), sulfonamides (32%), cephalosporins (15%), and nonsteroidal anti-inflammatory drugs (8%). The DAHT achieved acceptable test-retest reliability (median κ = 0.64, median agreement = 86%). The DAHT achieved a more complete allergy history than allergist documentation in the electronic health record, with lower median item uncertainty (21% DAHT vs 79% electronic health record) with fair concordance (median κ = 0.21, median agreement = 67%) between the two data sources.

conclusionThe DAHT is a reliable and valid source of patient-reported drug allergy information. This tool can be used in clinical care and clinical research to obtain standardized patient-reported drug allergy history.

Indexed as

Drug HypersensitivityMedical History TakingAdultAgedElectronic Health RecordsFemaleHumansMaleMiddle AgedReproducibility of ResultsSelf ReportSurveys and QuestionnairesconsensusDrug allergyhypersensitivityquestionnairereactionrisk stratification

Identifiers

PMID40049420
PMCPMC12353427

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.